BioNano Genomics Inc (NASDAQ:BNGO) was the target of a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 5,000 shares, a decline of 12.3% from the June 30th total of 5,700 shares. Based on an average trading volume of 14,200 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.1% of the shares of the company are short sold.

A number of equities research analysts have weighed in on BNGO shares. ValuEngine upgraded shares of BioNano Genomics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research downgraded shares of BioNano Genomics from a “hold” rating to a “sell” rating in a research note on Monday, July 8th. Finally, Maxim Group reiterated a “buy” rating and set a $7.00 price target on shares of BioNano Genomics in a research note on Friday, August 9th.

Shares of NASDAQ:BNGO traded up $0.09 on Thursday, hitting $1.95. The stock had a trading volume of 1,455 shares, compared to its average volume of 7,152. BioNano Genomics has a twelve month low of $1.44 and a twelve month high of $10.00. The company has a quick ratio of 5.64, a current ratio of 5.94 and a debt-to-equity ratio of 3.13. The company has a 50 day moving average of $2.46. The company has a market cap of $21.47 million and a P/E ratio of -0.75.

BioNano Genomics (NASDAQ:BNGO) last issued its earnings results on Thursday, August 8th. The company reported ($0.71) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.14). BioNano Genomics had a negative net margin of 247.03% and a negative return on equity of 249.06%. The firm had revenue of $2.18 million during the quarter, compared to analyst estimates of $2.56 million. On average, sell-side analysts forecast that BioNano Genomics will post -2.55 EPS for the current fiscal year.

A hedge fund recently bought a new stake in BioNano Genomics stock. Millennium Management LLC bought a new stake in BioNano Genomics Inc (NASDAQ:BNGO) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 48,399 shares of the company’s stock, valued at approximately $254,000. Millennium Management LLC owned approximately 0.48% of BioNano Genomics as of its most recent filing with the SEC. Institutional investors own 9.81% of the company’s stock.

About BioNano Genomics

Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.

Featured Article: What Factors Can Affect Return on Equity?

Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with's FREE daily email newsletter.